The therapeutic community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s exhibiting significant efficacy in clinical trials for treating obesity. Unlike some current weight loss approaches, retatrutide appears to offer a more substantial loss in body size and benefit metabolic function, particularly c